Receptos, Inc. (RCPT) Files $86.3M IPO
Tweet
Share
E-mail
Get Alerts RCPT Hot Sheet
Join SI Premium – FREE
Receptos, Inc. (Nasdaq: RCPT) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.3 million. Receptos plans to list on the NASDAQ Global Market under the symbol "RCPT."
The offering is being made through Credit Suisse, Leerink Swann, BMO Capital Markets, and Wedbush PacGrow Life Sciences.
Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics for immune disorders.
The offering is being made through Credit Suisse, Leerink Swann, BMO Capital Markets, and Wedbush PacGrow Life Sciences.
Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics for immune disorders.
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
